Drug Spending Growth Will Decelerate Due To Pricing Pressures, IQVIA Finds
Global spending on medicines will continue to increase through 2024, but at a lower rate than the previous five years due to the impact of discounts, rebates and patent expirations.
You may also be interested in...
Industry is limiting face-to-face interactions between sales reps and physicians, and some patients are sitting out visits, amid the COVID-19 outbreak. That poses big business challenges for pharma.
Coronavirus Update: Drug Launches Could Be Hit, New Twist In CureVac Controversy, Moderna Doses First Patient
As western Europe and the US roll out the next wave of lockdown measures to limit the spread of COVID-19, biopharma is continuing efforts to accelerate therapies and vaccines, including Moderna starting Phase I trials.
Historically low US brand price growth is one factor in a general slowdown in the annual growth rate of the global pharmaceutical market from 2019 through 2023, IQVIA forecasts in a new trends report.